3-oxo-1H-isobenzofuran-5-sulfonyl chloride | 56622-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异香豆素
• 英文名称: 3-oxo-1H-isobenzofuran-5-sulfonyl chloride
• 英文别名: 3-oxo-1,3-dihydroisobenzofuran-5-sulfonyl chloride；3-Oxo-1,3-dihydro-2-benzofuran-5-sulfonyl chloride；3-oxo-1H-2-benzofuran-5-sulfonyl chloride
• CAS: 56622-76-5
• 化学式: C₈H₅ClO₄S
• mdl: MFCD11179594
• 分子量: 232.644
• InChiKey: VZXTZCJLOJMGIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-oxo-1H-isobenzofuran-5-sulfonyl chloride 以65%的产率得到
  参考文献：
  名称：

  DCOSTA R.; NADKARNU V. V., J. INDIAN CHEM. SOC. , 1975, 52, NO 4, 333-334

  摘要：

  DOI：
• 作为产物：
  描述：

  苯酞 、 氯磺酸 以49%的产率得到
  参考文献：
  名称：

  DCOSTA R.; NADKARNU V. V., J. INDIAN CHEM. SOC. , 1975, 52, NO 4, 333-334

  摘要：

  DOI：

文献信息

• SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：AJINOMOTO CO., LTD.

  公开号：US20150051395A1

  公开（公告）日：2015-02-19

  Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

  提供的是具有特定化学结构的磺酰胺衍生物，在其末端有一个带有苯基或含杂原子的杂环基团作为取代基的磺酰胺基团，以及药用可接受的盐。这些化合物是具有卓越的α4整合素抑制作用的全新化合物。
• BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
  申请人：AMGEN INC.

  公开号：US20190077793A1

  公开（公告）日：2019-03-14

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

  本发明提供了一种式（I）的化合物或其药学上可接受的盐，包括本发明化合物的药物组合物，制造本发明化合物的方法以及它们的治疗用途。
• Bisamide sarcomere activating compounds and uses therof
  申请人：AMGEN INC.

  公开号：US10723720B2

  公开（公告）日：2020-07-28

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

  本发明提供了一种式（I）化合物或其药学上可接受的盐、包含本发明化合物的药物组合物、制造本发明化合物的方法及其治疗用途。
• Bisamide sarcomere activating compounds and uses thereof
  申请人：AMGEN INC.

  公开号：US10899746B2

  公开（公告）日：2021-01-26

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

  本发明提供了一种式（I）化合物或其药学上可接受的盐、包含本发明化合物的药物组合物、制造本发明化合物的方法及其治疗用途。
• Discovery of a Novel Noniminosugar Acid α Glucosidase Chaperone Series
  作者：Jingbo Xiao、Wendy Westbroek、Omid Motabar、Wendy A. Lea、Xin Hu、Arash Velayati、Wei Zheng、Noel Southall、Ann Marie Gustafson、Ehud Goldin、Ellen Sidransky、Ke Liu、Anton Simeonov、Rafael J. Tamargo、Antonia Ribes、Leslie Matalonga、Marc Ferrer、Juan J. Marugan

  DOI：10.1021/jm3005543

  日期：2012.9.13

  Pompe disease is an autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the lysosomal enzyme acid a-glucosidase (GAA). Many disease-causing mutated GAA retain enzymatic activity but are not translocated from endoplasmic reticulum (ER) to lysosomes. Enzyme replacement therapy (ERT) is the only treatment for Pompe disease but remains expensive, inconvenient, and does not reverse all disease manifestations. It was postulated that small molecules which aid in protein folding and translocation to lysosomes could provide an alternate to ERT. Previously, several iminosugars have been proposed as small-molecule chaperones for specific LSDs. Here we identified a novel series of noniminosugar chaperones for GAA. These moderate GAA inhibitors are shown to bind and thermostabilize GAA and increase GAA translocation to lysosomes in both wild-type and Pompe fibroblasts. AMDE and physical properties studies indicate that this series is a promising lead for further pharmacokinetic evaluation and testing in Pompe disease models.